Impact of Risankizumab on Patient-reported Outcomes and Biomarkers Over Time: Post-Hoc Analysis of Phase 3 INSPIRE and COMMAND Studies
Loading...
Contact
Check for full-text access
Issue Date
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Background: Patients with ulcerative colitis (UC) may experience debilitating symptoms that impact their quality of life. This post hoc analysis evaluates changes in patient-reported outcomes (PROs) and biomarkers over time during maintenance treatment with risankizumab (RZB), a specific inhibitor of IL-23, among patients who responded to RZB induction treatment.
Description
Citation
Publisher
License
Journal
Journal of Crohn's and Colitis